Literature DB >> 30482751

Disease-modifying therapies for multiple sclerosis.

Floriana De Angelis1, Nevin A John1, Wallace J Brownlee1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30482751     DOI： 10.1136/bmj.k4674

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  20 in total

Review 1.  Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.

Authors:  Carol Chase Huizar; Itay Raphael; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2020-09-20       Impact factor: 4.868

Review 2.  Exercise as Medicine in Multiple Sclerosis-Time for a Paradigm Shift: Preventive, Symptomatic, and Disease-Modifying Aspects and Perspectives.

Authors:  Ulrik Dalgas; Martin Langeskov-Christensen; Egon Stenager; Morten Riemenschneider; Lars G Hvid
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

3.  Understanding quality of life across different clinical subtypes of multiple sclerosis: a thematic analysis.

Authors:  Hikari Ando; Rosanna Cousins; Carolyn A Young
Journal:  Qual Life Res       Date:  2021-11-25       Impact factor: 4.147

Review 4.  Multiple Sclerosis: Systemic Challenges to Cost-Effective Care.

Authors:  David R Weinstein; Gary M Owens; Ankit Gandhi
Journal:  Am Health Drug Benefits       Date:  2022-03

5.  Development of a Prognostic Model for Predicting Multiple Sclerosis After Optic Neuritis: A Secondary Analysis of Data From the Optic Neuritis Treatment Trial.

Authors:  Wenjing Luo; Xinlei Deng; Xiaoyu Xu; Ruitong Song; Meifeng Luo; Heather E Moss; Yi Du
Journal:  J Neuroophthalmol       Date:  2021-10-22       Impact factor: 4.415

6.  Developing a community-engaged wheelchair exercise program for persons with MS: community advisory board formation and feedback.

Authors:  Stephanie L Silveira; Katherine Froehlich-Grobe; Robert W Motl
Journal:  Disabil Rehabil Assist Technol       Date:  2021-12-10

Review 7.  Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis.

Authors:  Anastasie M Dunn-Pirio; Benjamin M Heyman; Dan S Kaufman; Revere P Kinkel
Journal:  Curr Treat Options Neurol       Date:  2019-10-17       Impact factor: 3.598

8.  Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.

Authors:  Wei Zhen Yeh; Putu Ayu Widyastuti; Anneke Van der Walt; Jim Stankovich; Eva Havrdova; Dana Horakova; Karolina Vodehnalova; Serkan Ozakbas; Sara Eichau; Pierre Duquette; Tomas Kalincik; Francesco Patti; Cavit Boz; Murat Terzi; Bassem I Yamout; Jeannette Lechner-Scott; Patrizia Sola; Olga G Skibina; Michael Barnett; Marco Onofrj; Maria José Sá; Pamela Ann McCombe; Pierre Grammond; Radek Ampapa; Francois Grand'Maison; Roberto Bergamaschi; Daniele L A Spitaleri; Vincent Van Pesch; Elisabetta Cartechini; Suzanne Hodgkinson; Aysun Soysal; Albert Saiz; Melissa Gresle; Tomas Uher; Davide Maimone; Recai Turkoglu; Raymond Mm Hupperts; Maria Pia Amato; Franco Granella; Celia Oreja-Guevara; Ayse Altintas; Richard A Macdonell; Tamara Castillo-Trivino; Helmut Butzkueven; Raed Alroughani; Vilija G Jokubaitis
Journal:  Neurology       Date:  2021-04-20       Impact factor: 9.910

9.  COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.

Authors:  Afagh Garjani; Rodden M Middleton; Rachael Hunter; Katherine A Tuite-Dalton; Alasdair Coles; Ruth Dobson; Martin Duddy; Stella Hughes; Owen R Pearson; David Rog; Emma C Tallantyre; Roshan das Nair; Richard Nicholas; Nikos Evangelou
Journal:  Mult Scler Relat Disord       Date:  2021-05-05       Impact factor: 4.808

10.  Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis.

Authors:  Monica Barone; Laura Mendozzi; Federica D'Amico; Marina Saresella; Simone Rampelli; Federica Piancone; Francesca La Rosa; Ivana Marventano; Mario Clerici; Alessia d'Arma; Luigi Pugnetti; Valentina Rossi; Marco Candela; Patrizia Brigidi; Silvia Turroni
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.